Атеросклероз при АНЦА-ассоциированных системных васкулитах

1. <div><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеротромбоз при аутоиммунных заболеваниях: современное состояние проблемы. Cons Med: Болезни сердца и сосудов, 2010;1:15-9.</p><p>Leuven S.I., Franssen R., Kastelein J.J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008;47:3-7.</p><p>Ревматология: Национальное руководство. Под ред Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;647-61.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004.</p><p>Насонов Е.Л. Иммунологические маркеры атеросклероза. Тер арх 2002;5:80-5.</p><p>Елисеев М.С., Барскова В.Г., Насонов Е.Л. Роль фактора некроза опухоли-а (ФНО а) в развитии обменных нарушений и атеросклероза и влияние на них ингибиторов ФНО α у больных ревматическими заболеваниями. Науч-практич ревматол 2009;2:67-73.</p><p>Lang C.H., Dobrescu C., Bagby G.J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.</p><p>Chia S., Quadan M., Newton R. et al. Intra-arterial tumor necrosis factor-alpha impairs endothelialdependent dilatation in humans. Arterioscler Thromb Vasc Biol 2003;23:695-701.</p><p>Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.</p><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Интерлейкин-6 и сердечно-сосудистая патология при ревматоидном артрите. Науч-практич ревматол 2011;4:64-7.</p><p>Woods A., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000;21(19):1574-83.</p><p>Gotsman I., Stabholz A., Planer D. et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J 2008;10(7):494-8.</p><p>Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32(7):1213-8.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther 2008;10(2):30.</p><p>Kremers M.H., Crowson C., Nicola P. et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthr Rheum 2005;52:402-11.</p><p>Kremers M.H., Nicola P., Crowson C. et al. Cardiovascular death in rheumatoid arthritis. Arthr Rheum 2005;52:722-32.</p><p>Mansi S., Meilahn E., Rairie J. et al. Age specific incidence rates of myocardial infarction angina in women with systemic lupus erythematosus: comparison with the Framingem study. Am J Epidemiol 1997;145:408-15.</p><p>Gazi I.F., Boumpas D.T., Mikhailidis D. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007;25:102-11.</p><p>Westerweel P.E., Luyten R., Koomans H. et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthr Rheum 2007;56(5):1384-96.</p><p>Papadopoulos N.G., Alamanos Y., Voulgari P.V. et al. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005;23:861-6.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Науч-практич ревматол 2007;5:4-10.</p><p>Попкова Т.В., Новикова Д.С., Герасимова Е.В. и др. Метаболический синдром у больных системной красной волчанкой. Науч-практич ревматол 2008;4:14-20.</p><p>Roman M.J., Shanker B.A., Davis A. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.</p><p>Gonzalez A., Kremers M.H., Crowson C.S. et al. Survival trends and risk factors for mortality in rheumatoid arthritis. Int J Rheum 2005;3:38-46.</p><p>Qiao J.H., Castellani L.W., Fishbein M.C., Luis A.J. Immune complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler Thromb 1993;13:932-43.</p><p>Wick G., Romen M., Amberger A. et al. Atherosclerosis, autoimmunity, and vasculo-associated lymphoid tissue. FASEB J 1997;11:1199-207.</p><p>Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47.</p><p>Kallenberg C.G. Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allergy Immunol 2011;41(2):224-31.</p><p>Savage C.O.S., Williams J.M. Anti-endothelial cell antibodies in vasculitis. Am Soc Nephrol 2007;18:2424-6.</p><p>Wikk G., Millonig G., Xu Q. The autoimmune pathogenesis of atherosclerosis: an evolutionary-Darwinian concept. In: Shoenfeld Y., Harats D., Wick G., eds. Atherosclerosis and Autoimmunity. Amsterdam, Netherlands: Elsevier Publishers, 2001;5-13.</p><p>Sherer Y., Pagnoux C., Chironi G. et al. Carotid artery intima-media thickness, heat shock proteins and oxidized LDL autoantibodies in systemic necrotizing vasculitis. Rheum Int 2011;28:1099-103.</p><p>Swets B.P., Brouwer D.A.J., Cohen Tervaert J.W. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol 2001;124:163-7.</p><p>Faurschou M., Mellemkajer L., Sorensen I.J. et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulematosis. Arthr Rheum 2009;69(4):1187-92.</p><p>Моисеев С.В., Стрижаков Л.А., Диттерле В.Е. и др. Частота сердечно-сосудистых заболеваний у пациентов с системными васкулитами. Клин фарм тер 2011;20(3):30-4.</p><p>Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваск тер профилакт 2008;6(Прил. 2):1-32.</p><p>Salonen J.T., Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary artery disease. Arterioscler Thromb Vascul Biol 1991;11:1241-9.</p><p>Zaenker M., Aries P.M., Herlyn K. et al. Accelerated atherosclerosis in Wegener's granulomatosis (WG): a sonographic case-control study on intima media thickness. Arthr Rheum 2002;46:35-9.</p><p>de Leeuw K., Sanders J.S., Stegeman C. et al. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005;64:753-9.</p><p>Chironi G., Pagnoux C., Simon A. et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart 2007;93(1):96-9.</p><p>Mackenzie I.S., Wilkinson I.B., Cockcroft J.R. Assessment of arterial stiffness in clinical practice. QJM 2002;95:67-74.</p><p>Booth A.D., Wallace S., McEniery C.M. et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthr Rheum 2004;50:581-8.</p><p>Yildiz M., Soy M., Kurum T., Yildiz B.S. Arterial distensibility in Wegener's granulomatosis: a carotid-femoral pulse wave velocity study. Anadolu Kardiyol Derg 2007;7(3):281-5.</p><p>Рогоза А.Н., Балахонова Т.В., Чихладзе Н.М. Методы определения лодыжечно-плечевого индекса систолического давления при массовых обследованиях. Cons Med 2009;10:13-7.</p><p>Zheng Z.J., Sharrett A.R., Chambless L.E. et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997;131(1):115-25.</p><p>Sangle S.R., Davies R.J., Mora M. et al. Ankle-brachial pressure index: a simple tool for assessing cardiovascular risk in patients with systemic vasculitis. Rheumatology (Oxford) 2008;47:1058-60.</p><p>Peters M.J., Symmons D.P.M., McCarey D. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.</p><p>Peterson M.J., Symmons D.P., McCarrey D.W. et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - EULAR TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2008;67(Suppl. II):310.</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.</p><p>Van der Goes M.C., Jacobs J.W.G., Boers M. et al. Patients’ and rheumatologists’ perspectives on glucocorticoids an exercise to improve the implementation of the EULAR recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2009;10:235-9.</p></div><br />